1.0297

2.97% +0.0297

Talphera Inc (TLPH)

Overview News Price History Discussions Forecast

Talphera Inc stock is currently priced at $1.0297, with a 24-hour trading volume of 2,787. It has seen a +2.97% increased in the last 24 hours and a +4.86% rose in the past month. The chart indicates a potential bullish trend, as the stock is above the $1.02 pivot point. If it approaches the $1.04 resistance level, significant changes may occur.

Previous Close:

$1.00

Open:

24h Volume:

2,787

Market Cap:

$16.97M

Revenue:

$2.82M

Net Income/Loss:

$-18.40M

P/E Ratio:

EPS:

Net Cash Flow:

$-17.59M

1W Performance:

-8.06%

1M Performance:

+4.86%

6M Performance:

+0.00%

1Y Performance:

+0.00%

1D Range:

$1.00

$1.0248

52W Range:

$0.72

$1.61

Talphera Inc Stock (TLPH) Company Profile

Name

Talphera Inc

Sector

Healthcare (1193)

Industry

Drug Manufacturers - Specialty & Generic (4)

Phone

650-216-3500

Address

1850 GATEWAY DRIVE, SAN MATEO

Employee

Twitter

Next Earnings Date

2024-05-08

Latest SEC Filings

TLPH's Discussions on Twitter

Talphera Inc Stock (TLPH) Financials Data

Talphera Inc (TLPH) Revenue 2024

TLPH reported a revenue (TTM) of $2.82 million for the quarter ending December 31, 2021.

Talphera Inc (TLPH) Net Income 2024

TLPH net income (TTM) was -$18.40 million for the quarter ending December 31, 2023, a -138.52% decrease year-over-year.

Talphera Inc (TLPH) Cash Flow 2024

TLPH recorded a free cash flow (TTM) of -$17.59 million for the quarter ending December 31, 2023, a +38.69% increase year-over-year.

Talphera Inc (TLPH) Earnings per Share 2024

TLPH earnings per share (TTM) was -$1.44 for the quarter ending December 31, 2023, a -126.42% decline year-over-year.

Talphera Inc Stock (TLPH) Insider Trading

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total
Angotti Vincent J.	Chief Executive Officer	Sep 11 '23	Buy	0.80	10,000	7,950	91,805
Palmer Pamela P	Chief Medical Officer	Aug 25 '23	Sale	1.09	7,442	8,104	30,753
Palmer Pamela P	Chief Medical Officer	Aug 24 '23	Sale	1.17	9,514	11,131	38,195

Talphera Inc. is a pharmaceutical company focused on the development and commercialization of innovative therapies for use in medically supervised settings. Its product portfolio includes Niyad that is a lyophilized formulation of nafamostat. It is also developing two pre-filled syringes, a pre-filled ephedrine syringe, and PFS-02, a pre-filled phenylephrine syringe.